Beyond the stone: nephrolithiasis as a metabolic sentinel in upper tract urothelial carcinoma and papillary renal cell carcinoma: toward a risk-stratified management framework.

CONTEXT: Nephrolithiasis is increasingly recognized as a recurrent disorder that often coexists with broader metabolic vulnerability. Observational studies have also raised the possibility that stone disease may identify patients with a higher subsequent risk of upper tract urothelial carcinoma (UTUC) and, less consistently, renal cell carcinoma (RCC), particularly papillary RCC (pRCC).

OBJECTIVE

To critically review the epidemiologic and mechanistic literature linking nephrolithiasis to UTUC and RCC, distinguish association from causation, and outline a clinically practical risk-stratified framework.

EVIDENCE ACQUISITION: This narrative review was informed by targeted searches of population-based cohort studies, meta-analyses, guideline documents, and mechanistic studies relevant to nephrolithiasis, UTUC, RCC, obstruction, infection, inflammation, and metabolic dysregulation. Greater weight was given to subtype-specific epidemiologic studies and directly relevant upper-tract biology, whereas indirect mechanistic data were interpreted as emerging or hypothesis-generating.

EVIDENCE SYNTHESIS: The available literature supports three main conclusions. First, epidemiologic studies suggest an association between nephrolithiasis and increased risk of UTUC, with more limited and lower-specificity evidence for RCC, especially pRCC. Second, shared metabolic abnormalities-including obesity, diabetes, hypertension, dyslipidemia, smoking, and hyperuricemia-may contribute both to lithogenesis and to a pro-inflammatory milieu relevant to carcinogenesis. Third, mechanistic data support biologic plausibility through chronic obstruction, recurrent epithelial injury, crystal toxicity, inflammasome activation, and infection-related inflammation. However, surveillance bias, reverse causation, and heterogeneous endpoint definitions limit causal inference. Current evidence, therefore, supports nephrolithiasis as a clinically relevant marker of metabolic vulnerability and a possible biological contributor in selected contexts, rather than an established causal driver.

CONCLUSIONS

Current evidence does not support universal proactive intervention or routine oncologic surveillance for all stone formers. A more defensible clinical approach is risk stratification. Patients with recurrent, early-onset, infection-related, obstructive, or metabolically complicated stone disease may warrant intensified metabolic assessment, a lower threshold for selective stone-directed intervention in defined scenarios, and individualized follow-up. Dedicated cancer surveillance should remain selective and investigational pending prospective validation.